1. Home
  2. MBAI vs LNAI Comparison

MBAI vs LNAI Comparison

Compare MBAI & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.38

Market Cap

12.0M

Sector

N/A

ML Signal

N/A

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.33

Market Cap

11.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MBAI
LNAI
Founded
2004
N/A
Country
Israel
United States
Employees
85
29
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
11.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MBAI
LNAI
Price
$1.38
$0.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
102.5K
9.0M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$0.15
52 Week High
$3.92
$1.66

Technical Indicators

Market Signals
Indicator
MBAI
LNAI
Relative Strength Index (RSI) 40.73 46.45
Support Level $1.44 $0.27
Resistance Level $1.83 $0.54
Average True Range (ATR) 0.12 0.04
MACD -0.02 0.00
Stochastic Oscillator 23.95 44.27

Price Performance

Historical Comparison
MBAI
LNAI

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: